MRNA · News · 20260730N

Guidance / Outlook

Moderna, Inc. · 2026-07-30 · Importance 52 · Surprise 30

Analysts expect Moderna to report second-quarter 2026 revenue of approximately $103 million on July 31, 2026. Forecasts imply a 24.8% to 28% year-over-year revenue decline and a loss of roughly $1.97 to $2.00 per share. Investors are expected to focus on vaccine sales, cash burn, cost-reduction efforts, and the company’s strategy to diversify beyond COVID-19 vaccines.

Key facts

• Expectations of a $2 per share loss for Q2 were reiterated as part of Q2 earnings previews. source